With two McKinsey men as execs and with their McKinsey links world wide, I would hope they would want to get to the much more conclusive organoid test results next quarter and on the back of those results and an IND application, pick up additional funding by listing PYC on the NASDAQ. In the investor call they talked of Stoke Therapeutics who have listed on NASDAQ recently with similar stage tech and who are valued round AU$1.7Bill. Just my thoughts.
dyor
With two McKinsey men as execs and with their McKinsey links...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.24 |
Change
-0.035(2.75%) |
Mkt cap ! $711.5M | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.27 | $1.22 | $162.1K | 130.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 3818 | $1.22 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.24 | 2001 | 2 |
View Market Depth
| Last trade - 16.10pm 31/07/2025 (20 minute delay) ? |
| PYC (ASX) Chart |